Abstract
The efficacy of 131I therapy in achieving euthyroidism has been studied in a group of 264 patients followed for up to 10 yr. One hundred and eighty-six were given a dose adjusted for thyroid size and radioactive iodine uptake (Protocol 1), and a second group received the same dosage followed by antithyroid drug therapy plus potassium iodide for 15 days (Protocol 2). At 10-yr follow-up, 50–60% of patients were euthyroid. 25–29% of patients required 2 doses of 131I, and 4–5% required 3 doses. Fewer patients became hypothyroid when their pretreatment FTI was above the average value. More patients became hypothyroid, if their pretreatment test for antimic-rosomal antibodies was positive. Patients who required a second dose of radioactive iodide had a significantly greater chance of having worsening of their ophthalmopathy than those who became hypothyroid after the first dose. Treatment with radioactive iodide under either protocol appears to achieve euthyroidism at 10 yr with an incidence higher than that achieved by antithyroid drugs and comparable to that reported for subtotal thyroidectomy.
Similar content being viewed by others
References
Holm LE. Malignant disease following lodine-131 therapy in Sweden. In: Boice J.D., Fraumeni J.F. (Eds.), Progress in Cancer Research and Therapy. Radiation Carcinogenesis: Epidemiology and Biological Significance. Raven Press, New York, 1984, vol. 26, p. 263.
Safa A.M., Schumacher O.P., Rodriguez-Antunez A. Long-term follow-up results in children and adoles cents treated with radioactive iodine (131I) for hyper thyroidism. N. Engl. J. Med. 292: 167, 1975.
Beiling U., Einhorn J. Incidence of hypothyroidism and recurrences following 131I treatment of hyperthyroidism. Acta Radiol. 56:275, 1961.
Nofal M.M., Beierwaltes W.H., Patno M.E. Treatment of hyperthyroidism with sodium iodide I-131: A 16-year experience. JAMA 197: 605, 1966.
Hagen G.A., Ouellette R.P., Chapman E.M. Comparison of high and low dosage levels of 131I in the treatment of thyrotoxicosis. N.Engl. J. Med. 277:559,1975.
Smith R.N., Wilson G.M. Clinical trial of different doses of 131I in treatment of thyrotoxicosis. Br. Med. J. 7:129,1967.
Jackson G.L. Calculated low dose radioiodine therapy of thyrotoxicosis. Inter. J. Nucl. Med. Biol. 2: 80,1975.
Glennon J.A., Gordon E.S., Sawin CT. Hypothyroidism after low dose 131I treatment of hy perthyroidism. Ann. Intern. Med. 76: 721, 1972.
Sridama V., McCormick M., Kaplan E.L., Fauchet R., DeGroot L.J. Long-term follow-up study of compensated low-dose 131I therapy for Graves’ disease. N. Engl. J. Med. 311:426,1984.
Lamberg B.A., Salmi J., Wagar G., Makinen T. Spontaneous hypothyroidism after antithyroid treat ment of hyperthyroid Graves’ disease. J. Endocrinol. Invest. 4: 399, 1981.
Wise P.H., Burnet R.B., Ahmad A., Harding P.E. Intentional radioiodine ablation in Graves’ disease. Lancet 2:1231, 1975.
Rapoport B., Caplan R., DeGroot L.J. Low-dose sodium Iodine 131I therapy in Graves’ disease. JAMA 224: 1610,1973.
Roudebush C.P., Hoye K.E., DeGroot LJ. Compensated low-dose 131I therapy of Graves’ disease. Ann. Intern. Med. 87: 441,1977.
Steinbach J.J., Donoghue G.D., Goldman J.K. Simultaneous treatment of toxic diffuse goiter with I-131 and antithyroid drugs: A prospective study. J. Nucl. Med. 20:1263,1979.
Velkeniers B., Vanhaelst L, Cytryn R., Jonckheer M.H. Treatment of hyperthyroidism with radioiodine: adjunctive therapy with antithyroid drugs reconsidered. Lancet 7:1127,1988.
Ross D.S., Daniels G.H., De Stefano P., Maloof F., Ridgway E.C. Use of adjunctive potassium iodine after radioactive iodide (131I) treatment of Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 57: 250,1983.
Crooks J., Buchanan W.W, Wayne E.J., MacDonald E. Effect of pretreatment with methylthiouracil on results of 131I therapy. Br. Med. J. 7:151,1960.
Aro A., Huttunen J.K., Lamberg B.A., Pelkonen R., Ikkala E., Kuusisto A, Rissanen V., Salmi J., Tervonen S. Comparison of propranolol and Carbimazole as adjuncts to iodine-131 therapy of hyperthyroidism. Acta Endocrinol. (Copenh.) 96: 321,1981.
Refetoff S., Demeester-Mirkine N., Ermans A.M., De Groot LJ. Rapid control of thyrotoxicosis with combined 131I, antithyroid drugs, and potassium iodine therapy. J. Nucl. Med. Allied Sei. 21: 23,1977.
Holm LE., Alinder I. Relapses after thionamide therapy for Graves’ disease. Acta Med. Scand. 211: 489,1982.
Yamamoto M., Totsuka Y., Kojima I. Outcome of patients with Graves’ disease after long-term medical treatment guided by triiodothyronine (T3) suppression test. Clin. Endocrinol. (Oxf.) 19: 467,1983.
Lundell G., Holm LE., Ljunggren J.G., Wasserman J. Incidence of hypothyroidism after 131I therapy for hyperthyroidism. Acta Radiol. 20: 225,1981.
Saito S., Sakurada T., Yamamoto M. Long-term results of radioiodine (131I) therapy in 331 patients with Graves’ disease. Tokyo. J. Exp. Med. 132:1,1980.
Gwinup G., Elias A.N., Ascher M.S. Effect on exophthalmos of various methods of treatment of Graves’ disease. JAMA 247: 2135,1982.
Hamilton R.D., Mayberry W.E., McConahey W.M., Hanson K.C. Ophthalmopathy of Graves’ disease, a comparison between patients treated surgically and patients treated with radioiodide. Mayo Clin. Proc. 42: 812,1967.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeGroot, L.J., Mangklabruks, A. & McCormick, M. Comparison of RA 131I treatment protocols for Graves’ disease. J Endocrinol Invest 13, 111–118 (1990). https://doi.org/10.1007/BF03349519
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349519